70% versus 5%. That is the proptosis responder rate Viridian Therapeutics' Lumvoa (veligrotug-vvze) posted in its Phase 3 THRIVE trial — the number that convinced the FDA to approve the drug across both active and chronic thyroid eye disease (TED), a first for any therapy in this rare autoimmune disease.
THRIVE (active TED): 70% proptosis responder rate at week 15 vs 5% placebo; 67% composite overall responder rate vs 5%. Onset of effect observed as early as week 3.
THRIVE-2 (chronic TED): 56% proptosis responder rate vs 8% by Hertel measurement; 48% vs 3% by MRI/CT. First approved TED therapy with statistically significant effects on both diplopia response and complete resolution across both disease phases.
Thyroid eye disease is an autoimmune disorder triggered most often by Graves disease. The body's immune system attacks the tissue behind the eyes — orbital fibroblasts expressing the IGF-1 receptor proliferate, secrete glycosaminoglycans, and draw in fluid. The result: progressive proptosis (eye bulging), diplopia (double vision), pain, and in severe cases, vision loss. An estimated 15 to 20 people per 100,000 are affected annually, predominantly women in their 40s and 50s.
Until 2020, no pharmacologic treatment was approved for TED. Amgen's teprotumumab (Tepezza) broke that ground as an IGF-1R antagonist, but its label covered only active TED. Patients with chronic, less inflammatory disease — roughly half the TED population — had no approved medical option. Lumvoa closes that gap entirely.
The data that opened the label
Viridian ran two global Phase 3 trials back-to-back. THRIVE (NCT05176639) enrolled patients with active TED — Clinical Activity Score ≥4, proptosis ≥3 mm above normal, onset within 15 months. THRIVE-2 (NCT06021054) targeted the chronic population: any CAS, onset more than 15 months prior. Both used the same regimen: 10 mg/kg veligrotug intravenously every three weeks for five total infusions over 12 weeks.
Lumvoa — Phase 3 Active TED Efficacy
THRIVE enrolled 112 patients (2:1 randomization). Primary endpoint: proptosis responder rate at week 15 (≥2mm reduction). 70% of veligrotug-treated patients met the threshold vs 5% on placebo. The composite overall responder rate — proptosis + CAS + subjective assessment — reached 67% vs 5%. · Viridian Therapeutics, NEJM 2026
In the chronic TED cohort, the bar was higher. Patients with long-standing disease have fibrotic, less inflammation-driven tissue remodeling. Standard therapy has been observation or surgical decompression. THRIVE-2 enrolled 188 patients (2:1) and hit a 56% proptosis responder rate by Hertel measurement (48% by MRI/CT) versus 8% and 3% for placebo. Diplopia resolved completely in a statistically significant subset — an endpoint no approved TED drug had achieved across both disease states.
Adverse events were consistent with the IGF-1R antibody class. Muscle spasms (36% in THRIVE-2), menstrual disorders (33% of menstruating women), hearing impairment (13%), and hyperglycemia (10%) were the most common. Serious treatment-related events were rare: one grade 3 vertigo case in the chronic study. Ninety-four percent of patients completed the full treatment course.
How Lumvoa works differently
Veligrotug is a full antagonist monoclonal antibody targeting the insulin-like growth factor-1 receptor. Unlike partial inhibitors or antibodies with mixed agonist-antagonist profiles, full receptor blockade is designed to suppress orbital fibroblast activation more completely — though head-to-head mechanistic data against teprotumumab have not been published. The practical difference is in the regimen: five 30-to-45-minute infusions over 12 weeks versus eight infusions over 24 weeks for Tepezza.
The FDA granted Priority Review based on the Breakthrough Therapy Designation Viridian received in May 2025. The agency's decision came in under the six-month Priority Review clock, and the label carries no restriction on disease activity or duration — the first TED therapy with that breadth.
Market implications and the Amgen overhang
Tepezza generated approximately $2 billion in peak annual revenue for Amgen, making TED one of the more valuable rare-disease markets in biotech. Lumvoa enters a market with one entrenched competitor but with two structural advantages: broader labeling (active + chronic) and a shorter treatment course that may improve patient compliance and payer economics.
Viridian plans immediate launch with a dedicated patient support program (ViridianCares) providing insurance navigation and financial assistance. Its pipeline also includes elegrobart, a subcutaneous formulation targeting BLA submission in Q1 2027, which could further differentiate the franchise if approved — an at-home injection versus the current IV infusion model.
Three questions will define the commercial trajectory: whether payers restrict it to chronic TED patients first before allowing first-line use (mirroring the Tepezza access pattern), how physician adoption tracks between the two drugs given the lack of comparative data, and whether the hearing impairment signal — a known class effect — curbs uptake in older patients who may already have age-related hearing loss.
Q3 2026 earnings — first product revenue disclosure and reimbursement mix (commercial vs Medicare)
Elegrobart Phase 3 data — subcutaneous non-inferiority vs IV veligrotug, expected late 2026
Tepezza pricing response — Amgen may adjust contracting or pursue a chronic-TED label expansion of its own
TED diagnosis rates — broader awareness from two competing branded therapies may expand the addressable pool
What happens to the TED market a year from now?
Probability: 60% — First-mover inertia and established payer contracts for Tepezza will slow displacement, but the chronic-label gap is structural and cannot be closed without a supplementary Amgen filing.
✅ Arguments for
Five infusions vs eight is a concrete utilization difference payers track.
Breakthrough Therapy designation and Priority Review signal FDA confidence in the data package.
Confirmation criteria: Q3 2026 script data showing ≥1,500 new patient starts
❌ Arguments against
Hearing impairment signal may deter use in older patients who are already the highest-BMI TED cohort.
It has no commercial infrastructure at scale — first launch carries execution risk.
Disconfirmation criteria: Amgen files for chronic-TED label expansion within 6 months
Development scenarios
🟢 Optimistic scenario (25%)
Implications: Peak revenue potential of $3–4B, positioning it as a rare-disease specialty franchise with pipeline optionality.
🟡 Base-case scenario (55%)
Implications: Peak revenue of $1.5–2.5B — a solid rare-disease asset but not one that replaces the incumbent.
🔴 Pessimistic scenario (20%)
Implications: Peak revenue below $1B — it becomes an acquisition target for a larger rare-disease player that can absorb the commercial overhead.
